Search - tctmd.com

Displaying 761 - 780 of 1554

Sort: Relevancy | Date

News Conference News TCT 2015

Safety, Efficacy Endpoints Must Be Balanced in Clinical Trials

October 13, 2015

News Conference News TCT 2015

RIVER-PCI: No Advantage to Ranolazine in Patients With Incomplete Revascularization

Yael L. Maxwell

October 13, 2015

News Conference News TCT 2015

EXPLORE: Treating CTOs After STEMI Does Not Improve LV Function

Todd Neale

October 13, 2015

Presentation TCT 2015

Take-home Messages

Presenter: Matjaz Bunc, Christos Christou, Sasko Kedev, Milan A. Nedeljkovic, Georgios Sianos, Sinisa Stojkovic

October 12, 2015

Presentation TCT 2015

CTO Intervention in ACS With Complications: Case Reviews

Presenter: Matjaz Bunc, Christos Christou, Sasko Kedev, Milan A. Nedeljkovic, Georgios Sianos, Sinisa Stojkovic

October 12, 2015

Presentation TCT 2015

Transradial CTO Intervention With Complications: Case Reviews

Presenter: Matjaz Bunc, Christos Christou, Sasko Kedev, Milan A. Nedeljkovic, Georgios Sianos, Sinisa Stojkovic

October 12, 2015

Presentation TCT 2015

TAVR Complications: Case Reviews

Presenter: Matjaz Bunc, Christos Christou, Sasko Kedev, Milan A. Nedeljkovic, Georgios Sianos, Sinisa Stojkovic

October 12, 2015

Presentation TCT 2015

TAVR Complications: Case Reviews

Presenter: Matjaz Bunc, Christos Christou, Sasko Kedev, Milan A. Nedeljkovic, Georgios Sianos, Sinisa Stojkovic

October 12, 2015

Presentation TCT 2015

Introduction: CTO and TAVR in Everyday Practice

Presenter: Matjaz Bunc, Christos Christou, Sasko Kedev, Milan A. Nedeljkovic, Georgios Sianos, Sinisa Stojkovic

October 12, 2015

News Conference News TCT 2015

First-in-Human Studies: Novel Devices for Aortic Valve Stenosis Safe, Feasible

October 12, 2015

News Industry News

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

October 12, 2015

News Conference News TCT 2015

ABSORB II: Absorb BVS, Xience Yield Similar Outcomes at 2 Years

October 12, 2015

News Conference News TCT 2015

Cath Lab Economics: Pursuit of a Light at the End of the Tunnel

Nicole Lou

October 11, 2015

News Daily News

经桡动脉PCI可能会减弱比伐卢定的益处

Todd Neale

October 05, 2015

News Daily News

Transradial PCI May Attenuate Bivalirudin Benefits

Todd Neale

October 05, 2015

News Daily News

PCI Transradial podría atenuar los beneficios de la bivalirudina

Todd Neale

October 05, 2015

News Daily News

新型生物可吸收聚合物 SES 的良好结局持续 2 年

Yael L. Maxwell

October 02, 2015

News Daily News

Los Buenos Resultados de un Nuevo SLF de Polímero Bioabsorbibe se Mantienen a los 2 Años

Yael L. Maxwell

October 02, 2015

News Daily News

Good Outcomes of Novel Bioresorbable-Polymer SES Persist at 2 Years

Yael L. Maxwell

October 02, 2015

News Daily News

与预期相反，研究发现冠状动脉微血管功能障碍无性别差异

Yael L. Maxwell

September 23, 2015

Advertisement

Safety, Efficacy Endpoints Must Be Balanced in Clinical Trials

RIVER-PCI: No Advantage to Ranolazine in Patients With Incomplete Revascularization

EXPLORE: Treating CTOs After STEMI Does Not Improve LV Function

Take-home Messages

CTO Intervention in ACS With Complications: Case Reviews

Transradial CTO Intervention With Complications: Case Reviews

TAVR Complications: Case Reviews

TAVR Complications: Case Reviews

Introduction: CTO and TAVR in Everyday Practice

First-in-Human Studies: Novel Devices for Aortic Valve Stenosis Safe, Feasible

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

ABSORB II: Absorb BVS, Xience Yield Similar Outcomes at 2 Years

Cath Lab Economics: Pursuit of a Light at the End of the Tunnel

经桡动脉PCI可能会减弱比伐卢定的益处

Transradial PCI May Attenuate Bivalirudin Benefits

PCI Transradial podría atenuar los beneficios de la bivalirudina

新型生物可吸收聚合物 SES 的良好结局持续 2 年

Los Buenos Resultados de un Nuevo SLF de Polímero Bioabsorbibe se Mantienen a los 2 Años

Good Outcomes of Novel Bioresorbable-Polymer SES Persist at 2 Years

与预期相反，研究发现冠状动脉微血管功能障碍无性别差异

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content